脉冲场消融治疗阵发性房颤:AdmIRE关键性试验的安全性与有效性
AdmIRE是一项多中心单臂FDA IDE研究,纳入277例药物难治性症状性阵发性房颤患者,使用整合电解剖标测系统的可变环脉冲场消融导管行肺静脉隔离。主要不良事件率为2.9%,12个月主要有效性终点为74.6%,术后1年房颤/房速/房扑无复发率为75.4%,生活质量和医疗资源使用指标早期改善。
要点
- 可变环脉冲场消融导管整合标测系统,主要不良事件率2.9%
- 12个月主要有效性复合终点达74.6%,1年无复发率75.4%
- 超过25%手术无透视完成,中位肺静脉隔离时间81分钟
核心结论
- AdmIRE试验证实可变环脉冲场消融导管治疗阵发性房颤安全有效,手术和消融时间短且透视暴露低。
研究设计与样本
- 多中心单臂FDA研究性器械豁免研究,30个中心纳入277例药物难治性症状性阵发性房颤患者(61.5±10.3岁,64.3%男性)。
主要发现
- 主要不良事件率为2.9%(8/272),最常见并发症为心包填塞。
- 12个月主要有效性复合终点为74.6%,术后1年房颤、房速或房扑无复发率为75.4%。
- 中位肺静脉隔离手术时间、透视时间和脉冲场消融应用时间分别为81.0(61.0,112.0)、7.1(0.00,14.3)和31.0(24.8,40.9)分钟。
- 超过25%的手术在无透视下完成,术后3个月起生活质量显著改善并伴随多种医疗资源使用指标下降。
关键数值与推荐
- 主要安全终点为消融后7天内主要不良事件。
- 主要有效性终点为12个月无记录到的房性快速性心律失常发作、未达到肺静脉隔离、未使用非研究导管行肺静脉隔离、未重复手术(空白期一次重做除外)、空白期后未启用新或既往失败I/III类抗心律失常药物更高剂量、空白期后未行直流电复律的复合终点。
临床怎么用
- 对于药物难治性症状性阵发性房颤,可考虑使用整合标测系统的可变环脉冲场消融导管行肺静脉隔离,以缩短手术时间并减少透视暴露。
局限性
- 本研究为单臂设计,未设对照组,结果需在随机对照研究中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence from clinical trials of early pulsed field ablation (PFA) systems in treating atrial fibrillation has demonstrated their promising potential to reduce complications associated with conventional thermal modalities while maintaining efficacy. However, the lack of a fully integrated mapping system, a staple technology of most modern electrophysiology procedures, poses limitations in lesion creation and workflow options. A novel variable-loop PFA catheter integrated with an electroanatomic mapping system has been developed that allows for real-time nonfluoroscopic procedural guidance and lesion indexing as well as feedback of tissue-to-catheter proximity. AdmIRE (Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the Bosense-Webster Irreversible Electroporation Ablation System), a multicenter, single-arm, Food and Drug Administration investigational device exemption study, evaluated the long-term safety and effectiveness of this integrated PFA system in a large United States-based drug-refractory symptomatic paroxysmal atrial fibrillation patient population. METHODS: Using the PFA catheter with a compatible electroanatomic mapping system, patients with drug-refractory symptomatic paroxysmal atrial fibrillation underwent pulmonary vein isolation. The primary safety end point was primary adverse event within 7 days of ablation. The primary effectiveness end point was a composite end point that included 12-month freedom from documented atrial tachyarrhythmia (ie, atrial fibrillation, atrial tachycardia, atrial flutter) episodes, failure to achieve pulmonary vein isolation, use of a nonstudy catheter for pulmonary vein isolation, repeat procedure (except for one redo during blanking), taking a new or previously failed class I or III antiarrhythmic drug at higher dose after blanking, or direct current cardioversion after blanking. RESULTS: At 30 centers, 277 patients with paroxysmal atrial fibrillation (61.5±10.3 years of age; 64.3% male) in the pivotal cohort underwent PFA. More than 25% of the procedures were performed without fluoroscopy. Median (Q1, Q3) pulmonary vein isolation procedure, fluoroscopy, and transpired PFA application times were 81.0 (61.0, 112.0), 7.1 (0.00, 14.3), and 31.0 (24.8, 40.9) minutes, respectively. The primary adverse event rate was 2.9% (8 of 272), with the most common complication being pericardial tamponade. The 12-month primary effectiveness end point was 74.6%. The 1-year freedom from atrial fibrillation, atrial tachycardia, or atrial flutter recurrence rate after blanking was 75.4%. Substantial improvements in quality of life were observed as early as 3 months after the procedure, concurrent with a reduction in multiple health care use measures. CONCLUSIONS: AdmIRE confirmed the safety and effectiveness of the variable-loop PFA catheter, with short procedure and PFA application times and low fluoroscopy exposure. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05293639.
引用
- Reddy VY, Calkins H, Mansour M, et al. Pulsed Field Ablation to Treat Paroxysmal Atrial Fibrillation: Safety and Effectiveness in the AdmIRE Pivotal Trial. Circulation. 2024. PMID: 39258362. doi:10.1161/CIRCULATIONAHA.124.070333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。